Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2017 Aug 12

PMID 28798935

Citations 24

Authors

Marzena Laskowska

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to determine whether maternal serum matrix metalloproteinases 2, 3, 9, and 13 levels differ in early- and late-onset preeclampsia and uncomplicated pregnancies.

Patients And Methods: The study was carried out in 125 pregnant women (29 with early-onset preeclampsia; 31 preeclamptic patients with late-onset preeclampsia; and 65 healthy pregnant controls). Levels of MMP-2, MMP-3, MMP-9, and MMP-13 were measured in the maternal serum using an enzyme-linked immunosorbent assay.

Results: Maternal serum MMP-2 levels in both the groups of preeclamptic women were significantly higher than those in the controls. Levels of MMP-3 were significantly higher in preeclamptic patients with early-onset disease; however, the MMP-3 levels in patients with late-onset preeclampsia were similar to those observed in the control subjects. MMP-9 levels were lower whereas the levels of MMP-13 were higher in both preeclamptic groups of pregnant women than in the healthy controls, but these differences were statistically insignificant.

Conclusions: One important finding of the present study was that MMP-3 appears to be involved solely in early-onset preeclampsia, but not in late-onset preeclampsia. Higher levels of MMP-2 and MMP-13 and lower levels of MMP-9 seem to be related to both early- and late-onset severe preeclampsia.

Citing Articles

APOA1 Is a Novel Marker for Preeclampsia.

Liu Z, Pei J, Zhang X, Wang C, Tang Y, Liu H Int J Mol Sci. 2023; 24(22).

PMID: 38003549 PMC: 10671820. DOI: 10.3390/ijms242216363.

Matrix metalloproteinase-3 in preeclamptic and normotensive pregnancies complicated by foetal growth restriction.

Laskowska M, Dymara-Konopka W, Szmit E, Ledwich-Kibicka D, Wrobel A Heliyon. 2023; 9(7):e18105.

PMID: 37483829 PMC: 10362329. DOI: 10.1016/j.heliyon.2023.e18105.

Oral nifedipine and phytosterol, intravenous nicardipine, and oral nifedipine only: Three-arm, retrospective, cohort study for management of severe preeclampsia.

Ma S, Zhu L, Zhou T, Qi T, Wang W Open Life Sci. 2023; 18(1):20220581.

PMID: 37250848 PMC: 10224616. DOI: 10.1515/biol-2022-0581.

Pravastatin Prevents Increases in Activity of Metalloproteinase-2 and Oxidative Stress, and Enhances Endothelium-Derived Nitric Oxide-Dependent Vasodilation in Gestational Hypertension.

Toghi C, Martins L, Pacheco L, Caetano E, Mattos B, Rizzi E Antioxidants (Basel). 2023; 12(4).

PMID: 37107314 PMC: 10135677. DOI: 10.3390/antiox12040939.

Mouse models of preeclampsia with preexisting comorbidities.

Waker C, Hwang A, Bowman-Gibson S, Chandiramani C, Linkous B, Stone M Front Physiol. 2023; 14:1137058.

PMID: 37089425 PMC: 10117893. DOI: 10.3389/fphys.2023.1137058.

References

Maquoi E, Polette M, Nawrocki B, Bischof P, Noel A, Pintiaux A . Expression of stromelysin-3 in the human placenta and placental bed. Placenta. 1997; 18(4):277-85. DOI: 10.1016/s0143-4004(97)80062-8. View

Redman C, Sargent I, Staff A . IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia?. Placenta. 2014; 35 Suppl:S20-5. DOI: 10.1016/j.placenta.2013.12.008. View

Lockwood C, Basar M, Kayisli U, Guzeloglu-Kayisli O, Murk W, Wang J . Interferon-γ protects first-trimester decidual cells against aberrant matrix metalloproteinases 1, 3, and 9 expression in preeclampsia. Am J Pathol. 2014; 184(9):2549-59. PMC: 4188280. DOI: 10.1016/j.ajpath.2014.05.025. View

Pizon T, Rajzer M, Wojciechowska W, Rojek M, Kameczura T, Jurczyszyn A . [The influence of antihypertensive treatment on arterial stiffness, shear stress and activity of chosen matrix metalloproteinases]. Przegl Lek. 2016; 72(2):53-9. View

Sternlicht M, Bissell M, Werb Z . The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene. 2000; 19(8):1102-13. PMC: 2933206. DOI: 10.1038/sj.onc.1203347. View

Prochazka M, Prochazkova J, Lubusky M, Pilka R, Ulehlova J, Michalec I . Markers of endothelial activation in preeclampsia. Clin Lab. 2015; 61(1-2):39-46. View

Poon L, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides K . First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome. Prenat Diagn. 2009; 29(6):553-9. DOI: 10.1002/pd.2234. View

Narumiya H, Zhang Y, Guilbert L, Davidge S . Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy. 2002; 20(2):185-94. DOI: 10.1081/PRG-100106968. View

Gerlach R, Demacq C, Jung K, Tanus-Santos J . Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem. 2006; 40(1-2):119-23. DOI: 10.1016/j.clinbiochem.2006.10.007. View

10.

Husslein H, Haider S, Meinhardt G, PRAST J, Sonderegger S, Knofler M . Expression, regulation and functional characterization of matrix metalloproteinase-3 of human trophoblast. Placenta. 2009; 30(3):284-91. PMC: 2974218. DOI: 10.1016/j.placenta.2008.12.002. View

11.

Myers J, Merchant S, Macleod M, Mires G, Baker P, Davidge S . MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Hypertens Pregnancy. 2005; 24(2):103-15. DOI: 10.1081/PRG-200059836. View

12.

Visse R, Nagase H . Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92(8):827-39. DOI: 10.1161/01.RES.0000070112.80711.3D. View

13.

Sun C, Zhang Q, Hu B, Zhang K . Investigation of the association between matrix metalloproteinase-9 genetic polymorphisms and development of pre-eclampsia in Chinese pregnant women. Genet Mol Res. 2016; 15(3). DOI: 10.4238/gmr.15038355. View

14.

Newby A . Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2005; 69(3):614-24. DOI: 10.1016/j.cardiores.2005.08.002. View

15.

Borzychowski A, Sargent I, Redman C . Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006; 11(5):309-16. DOI: 10.1016/j.siny.2006.04.001. View

16.

Trojanek J . [Role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in hypertension. Pathogenesis of hypertension and obesity]. Postepy Biochem. 2016; 61(4):356-63. View

17.

Whitley G, Cartwright J . Cellular and molecular regulation of spiral artery remodelling: lessons from the cardiovascular field. Placenta. 2010; 31(6):465-74. PMC: 2882556. DOI: 10.1016/j.placenta.2010.03.002. View

18.

Merchant S, Davidge S . The role of matrix metalloproteinases in vascular function: implications for normal pregnancy and pre-eclampsia. BJOG. 2004; 111(9):931-9. DOI: 10.1111/j.1471-0528.2004.00223.x. View

19.

Huppertz B, Kertschanska S, Demir A, Frank H, Kaufmann P . Immunohistochemistry of matrix metalloproteinases (MMP), their substrates, and their inhibitors (TIMP) during trophoblast invasion in the human placenta. Cell Tissue Res. 1998; 291(1):133-48. DOI: 10.1007/s004410050987. View

20.

McKirdy A, Marks L . PP060. Matrix metalloproteinases-2 and -9 and their inhibitors: A role in the development of pre-eclampsia?. Pregnancy Hypertens. 2015; 2(3):274-5. DOI: 10.1016/j.preghy.2012.04.171. View